Powder -20°C 3 years; 4°C 2 years In solvent -80°C 6 months;-20°C 1 month
Research Area:
Cancer
Target:
IC50: 14 nM (HER2), 12 nM (EGFR)[3]
Description:
Sapitinib is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3, exhibiting inhibitory activity against HER2 and EGFR with IC50 14 and 12 nM, respectively.